<DOC>
<DOCNO>EP-0642531</DOCNO> 
<TEXT>
<INVENTION-TITLE>
MONOMER AND DIMER PEPTIDES, UTILIZATION AS CYTOPROTECTOR AGENTS AND PREPARATION METHOD
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3800	A61P4300	C07K14435	C07K1452	A61K3800	C07K706	A61K3819	C07K700	C07K104	C07K1113	A61K3819	C07K14745	A61P4300	C07K100	C07K708	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61P	C07K	C07K	A61K	C07K	A61K	C07K	C07K	C07K	A61K	C07K	A61P	C07K	C07K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K38	A61P43	C07K14	C07K14	A61K38	C07K7	A61K38	C07K7	C07K1	C07K1	A61K38	C07K14	A61P43	C07K1	C07K7	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
INST VAISSEAUX ET DU SANG
</APPLICANT-NAME>
<APPLICANT-NAME>
INSTITUT DES VAISSEAUX ET DU SANG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
AMIRAL JEAN
</INVENTOR-NAME>
<INVENTOR-NAME>
CAEN JACQUES PHILIPPE
</INVENTOR-NAME>
<INVENTOR-NAME>
HAN ZHONG CHAO
</INVENTOR-NAME>
<INVENTOR-NAME>
AMIRAL, JEAN
</INVENTOR-NAME>
<INVENTOR-NAME>
CAEN, JACQUES, PHILIPPE
</INVENTOR-NAME>
<INVENTOR-NAME>
HAN, ZHONG, CHAO
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of a peptide substance, wherein a peptide 
substance whose structure contains 


(a) a first fragment of the formula 

Asx-A
1
-A
2
   (F
1
)
 
in which 


Asx is Asp or Asn, 
A
1
 is Gly, MeGly, EtGly or Aib and 
A
2
 is Arg, Dbu, His, Lys or Orn, and 
(b) a second fragment of the formula 

A
3
-Cys-A
4
-Asx   (F
2
)
 
in which 


A
3
 is Leu, Ile, Nle, Val, Nva, Ahe, Acp or Cle, 
A
4
 is Leu, Ile, Nle, Val, Nva, Ahe, Acp or Cle and 
Asx is Asp or Asn, as indicated above, the second 
fragment (F
2
) being nearer the C-terminal end than 
the first fragment (F
1
), 
 
is used for the preparation of a cytoprotective drug 

useful for combating cytotoxic aggression. 
Use according to claim 1 wherein a peptide substance 

(1) which has megakaryocyte-inhibiting properties and 
(2) whose structure contains 

(a) a first fragment of the formula 

Asx-A
1
-A
2
   (F
1
)
 
in which 


Asx is Asp or Asn, 
A
1
 is Gly, MeGly, EtGly or Aib and 
A
2
 is Arg, Dbu, His, Lys or Orn, and 
(b) a second fragment of the formula 

A
3
-Cys-A
4
-Asx   (F
2
)
 
in which 


A
2
 is Leu, Ile, Nle, Val, Nva, Ahe, Acp or Cle, 
A
4
 is Leu, Ile, Nle, Val, Nva, Ahe, Acp or Cle  
 

and 
Asx is Asp or Asn, as indicated above, the 
second fragment (F
2
) being nearer the C-terminal end 
than the first fragment (F
1
), 
 
is used for the preparation of a cytoprotective drug 

for combating cytotoxic therapy, especially- chemotherapy 
and autografts. 
Use according to claim 1 or 2 wherein the peptide 
substance contains the fragment (F
1
) joined to the 
fragment (F
2
) 
via
 an amino acid to give the structure 

F
1
-A
5
-F
2
    (F
3
)
 
in which A
5
 is an amino acid residue containing a 
basic, acidic or amido side-group and F
1
 and F
2
 are 
defined as indicated above. 
Use according to claim 3 wherein A
5
 is Arg, 
Lys, His, Orn, Dbu, Glu, Gln, Asp, Asn, Aad or Dpr. 
Use according to any one of claims 1 to 3 
wherein the peptide substance has a monomeric structure 

of the formula 

R-B
1
-Asx-A
1
-A
2
-A
5
-A
3
-Cys-A
4
-Asx-B
2
-R'
 
or a dimeric structure of the formula 


 
in which A
1
, A
2
, A
3
, A
4
 and A
5
 are defined as indicated 
above, 


B
1
 is a single bond, an amino acid group or a peptide 
residue having from 2 to 10 amino acid groups, 
B
2
 is an amino acid group or a peptide residue having 
from 2 to 14 amino acid groups, the amino acid at the 

C-terminal end of B
2
 having a cyclic structure and 
being selected from the group consisting of Pro, 3Hyp, 

4Hyp, ATC, Aze, Pip, Cle, ACC and Pyr, 
R is H or a protecting group for the NH
2
 group at the 
N-terminal end, and  

 
R' is OH or a protecting group for the COOH group at 
the C-terminal end. 
Use according to claim 5 wherein (i) the amino 
acid or amino acids included in B
1
 and (ii) the amino 
acid or amino acids included in B
2
, other than the one 
at the C-terminal end, are selected from the group 

consisting of Ala, Phe, cyclohexylalanine (CHA), cyclohexylglycine 
(CHG), cyclopentylalanine (CPA), cyclopentylglycine 

(CPG), Tyr, 3-(4-hydroxycyclohexyl)glycine 
(CHU), 3-(4-hydroxycyclohexyl)alanine (CHT), Leu, Ile, 

Nle, Val, Nva, Ahe, Acp, Arg, Lys, His, Orn, Dbu, Glu, 
GIn, Asp, Asn, Aad, Dpr, Ser, Gly, MeGly, EtGly, Aib, 

Thr, pipecolic acid (Pip), Pro, 3Hyp, 4Hyp, ATC, Aze, 
Pip, Cle, ACC and Pyr. 
Use according to any one of claims 1, 2 and 3 
wherein the peptide substance is selected from the 

group consisting of pF4, native pF4, recombinant pF4 
and mixtures thereof. 
Use according to any one of claims 1, 2 and 3 
wherein the peptide substance is selected from the 

group consisting of LA-pF4, βTG, IL8, CTAP-III and 
mixtures thereof. 
Use according to claim 5 wherein the peptide 
substance is selected from the group consisting of the 

monomeric dodecapeptide of the formula 

 
its dimer of the formula 


 
and mixtures thereof. 
A peptide substance which has a monomeric 
structure of the formula 


R-B
1
-Asx-A
1
-A
2
-A
5
-A
3
-Cys-A
4
-Asx-B
2
-R'
 
or a dimeric structure of the formula  

 

 
in which A
1
, A
2
, A
3
, A
4
 and A
5
 are defined as indicated 
above, 


B
1
 is a single bond, an amino acid group or a peptide 
residue having from 2 to 10 amino acid groups, 
B
2
 is an amino acid group or a peptide residue having 
from 2 to 14 amino acid groups, the amino acid at the 

C-terminal end of B
2
 having a cyclic structure and 
being selected from the group consisting of Pro, 3Hyp, 

4Hyp, ATC, Aze, Pip, Cle, ACC and Pyr, 
R is H or a protecting group for the NH
2
 group at the 
N-terminal end, and 
R' is OH or a protecting group for the COOH group at 
the C-terminal end. 
A peptide substance according to claim 10 
wherein (i) the amino acid or amino acids included in 

B
1
 and (ii) the amino acid or amino acids included in 
B
2
, other than the one at the C-terminal end, are 
selected from the group consisting of Ala, Phe, cyclohexylalanine 

(CHA), cyclohexylglycine (CHG), cyclopentylalanine 
(CPA), cyclopentylglycine (CPG), Tyr, (4-hydroxycyclohexyl)glycine 

(CHU), (4-hydroxycyclohexyl)alanine 
(CHT), Leu, Ile, Nle, Val, Nva, Ahe, Acp, Arg, 

Lys, His, Orn, Dbu, Glu, Gln, Asp, Asn, Aad, Dpr, Ser, 
Gly, MeGly, EtGly, Aib, Thr, pipecolic acid (Pip), Pro, 

3Hyp, 4Hyp, ATC, Aze, Pip, Cle, ACC and Pyr. 
A peptide substance according to claim 10 which 
is selected from the group consisting of the monomeric 

dodecapeptide of the formula 

 
its dimer of the formula  

 

 
and mixtures thereof. 
A method of preparing a compound of formula I 
or II, said method, which involves a sequential peptide 

synthesis in a heterogeneous reaction medium and a 
purification step, comprising 


(a) using a reducing agent 

(i) in the reaction medium as from the moment 
when Cys enters the synthesis of said monomeric peptide, 

or subsequently, 
(ii) before and/or after purification, 
 
so as to reduce substantially or prevent the production 

of the dimeric peptide of formula II which results from 
the formation of a disulfide bridge -S-S- between the 

Cys of two monomeric chains, in order to obtain a compound 
of formula I, and 
(b) if necessary, forming said -S-S- bridge 
via
 the Cys 
of two monomeric chains, in order to obtain a compound 

of formula II. 
Use of a peptide substance selected from the 
group consisting of the monomeric peptides of formula I 

and the dimeric peptides of formula II according to 
claim 10 and mixtures thereof for the preparation of a 

megakaryocyte-inhibiting drug for combating thrombocytemia. 
Use according to claim 14 wherein the peptide 
substance is selected from the monomeric dodecapeptide 

of the formula 

 
its dimer of the formula 


 
and mixtures thereof. 
</CLAIMS>
</TEXT>
</DOC>
